Find Vilazodone manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Related ProductsRelated Products

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

API REF. PRICE (USD/KG)

MARKET PLACE

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

Finished Drug Prices

NA

113 RELATED EXCIPIENT COMPANIES

178EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 163521-12-8, 5-(4-(4-(5-cyano-1h-indol-3-yl)butyl)piperazin-1-yl)benzofuran-2-carboxamide, Emd 515259, Emd-515259, Emd-68-843, 5-[4-[4-(5-cyano-1h-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide
Molecular Formula
C26H27N5O2
Molecular Weight
441.5  g/mol
InChI Key
SGEGOXDYSFKCPT-UHFFFAOYSA-N
FDA UNII
S239O2OOV3

Vilazodone
A benzofuran, indole, and piperazine derivative that functions as a SEROTONIN UPTAKE INHIBITOR and partial SEROTONIN 5-HT1 RECEPTOR AGONIST. It is used as an ANTIDEPRESSIVE AGENT.
1 2D Structure

Vilazodone

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide
2.1.2 InChI
InChI=1S/C26H27N5O2/c27-16-18-4-6-23-22(13-18)19(17-29-23)3-1-2-8-30-9-11-31(12-10-30)21-5-7-24-20(14-21)15-25(33-24)26(28)32/h4-7,13-15,17,29H,1-3,8-12H2,(H2,28,32)
2.1.3 InChI Key
SGEGOXDYSFKCPT-UHFFFAOYSA-N
2.1.4 Canonical SMILES
C1CN(CCN1CCCCC2=CNC3=C2C=C(C=C3)C#N)C4=CC5=C(C=C4)OC(=C5)C(=O)N
2.2 Other Identifiers
2.2.1 UNII
S239O2OOV3
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 2-benzofurancarboxamide, 5-(4-(4-(5-cyano-1h-indol-3-yl)butyl)-1-piperazinyl)-, Hydrochloride (1:1)

2. 5-(4-(4-(5-cyano-3-indolyl)butyl)-1-piperazinyl)benzofuran-2-carboxamide

3. 68843, Emd

4. Emb 68843

5. Emb-68843

6. Emb68843

7. Emd 68843

8. Hcl, Vilazodone

9. Hydrochloride, Vilazodone

10. Viibryd

11. Vilazodone Hcl

12. Vilazodone Hydrochloride

2.3.2 Depositor-Supplied Synonyms

1. 163521-12-8

2. 5-(4-(4-(5-cyano-1h-indol-3-yl)butyl)piperazin-1-yl)benzofuran-2-carboxamide

3. Emd 515259

4. Emd-515259

5. Emd-68-843

6. 5-[4-[4-(5-cyano-1h-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide

7. 5-{4-[4-(5-cyano-1h-indol-3-yl)butyl]piperazin-1-yl}-1-benzofuran-2-carboxamide

8. Chembl439849

9. S239o2oov3

10. Chebi:70707

11. Vilazodone [inn]

12. Emd 68843 (hydrochloride);sb659746a (hydrochloride)

13. 5-(4-(4-(5-cyanoindol-3-yl)butyl)-1-piperazinyl)-2-benzofurancarboxamide

14. 2-benzofurancarboxamide, 5-[4-[4-(5-cyano-1h-indol-3-yl)butyl]-1-piperazinyl]-

15. Vilazodone [usan:inn]

16. Vilazodona

17. Vilazodonum

18. Unii-s239o2oov3

19. Hsdb 8197

20. 2-benzofurancarboxamide, 5-(4-(4-(5-cyano-1h-indol-3-yl)butyl)-1-piperazinyl)-

21. 5-(4-[4-(5-cyano-1h-indol-3-yl)butyl]piperazin-1-yl)benzofuran-2-carboxamide

22. Vilazodone [mi]

23. Vilazodone (usan/inn)

24. Vilazodone [usan]

25. Vilazodone [vandf]

26. Vilazodone [mart.]

27. Vilazodone [who-dd]

28. Schembl650682

29. Gtpl7427

30. Yl}-1-benzofuran-2-carboxamide

31. Dtxsid80870086

32. Ex-a174

33. Hms3744c03

34. Hms3886n05

35. Amy22748

36. Bcp05225

37. Zinc1542113

38. Bdbm50151982

39. Mfcd09838919

40. S5858

41. 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine

42. Akos015924744

43. Cs-0550

44. Db06684

45. Pb25213

46. Sb20296

47. Ncgc00371130-03

48. Ncgc00371130-06

49. Ac-25886

50. As-73542

51. Hy-14262

52. Emd 68843;sb 659746a

53. Ft-0675813

54. D09698

55. Ab01563299_01

56. A900227

57. L001518

58. Q408588

59. 5-{4-[4-(5-cyano-1h-indol-3-yl)butyl]piperazin-1-

60. F0001-2418

61. 1-[4-(5-cyanoindol-3-yl)butyl]4-(2-carbamoyl-benzofuran-5-yl)-piperazine

62. 5-{4-[4-(5-cyano-3-indolyl)butyl]-1-piperazinyl}benzo-furan-2-carboxamide

63. 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine

64. 5 -(4-(4-(5 -cyano-1h-indol-3 -yl)butyl)piperazin-1 -yl)benzofuran-2-carboxamide

65. 5-[4-[4-(5-cyanoindol-3-yl)butyl]piperazin-1-yl]benzofuran-2-carboxamide

66. 5-{4-[4-(5-cyano-1h-indol-3-yl)-butyl]-piperazin-1-yl}-benzofuran-2-carboxylic Acid Amide

2.4 Create Date
2006-07-28
3 Chemical and Physical Properties
Molecular Weight 441.5 g/mol
Molecular Formula C26H27N5O2
XLogP34
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count5
Rotatable Bond Count7
Exact Mass441.21647512 g/mol
Monoisotopic Mass441.21647512 g/mol
Topological Polar Surface Area102 Ų
Heavy Atom Count33
Formal Charge0
Complexity729
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameViibryd
PubMed HealthVilazodone (By mouth)
Drug ClassesAntidepressant
Drug LabelVIIBRYD Tablets for oral administration contain polymorph Form IV vilazodone hydrochloride (HCl), a selective serotonin reuptake inhibitor and a 5HT1A receptor partial agonist.Vilazodone HCl is 2-benzofurancarboxamide, 5-[4-[4-(5-cyano-1H-indol-3-yl)...
Active IngredientVilazodone hydrochloride
Dosage FormTablet
RouteOral
Strength10mg; 40mg; 20mg
Market StatusPrescription
CompanyForest Labs

2 of 2  
Drug NameViibryd
PubMed HealthVilazodone (By mouth)
Drug ClassesAntidepressant
Drug LabelVIIBRYD Tablets for oral administration contain polymorph Form IV vilazodone hydrochloride (HCl), a selective serotonin reuptake inhibitor and a 5HT1A receptor partial agonist.Vilazodone HCl is 2-benzofurancarboxamide, 5-[4-[4-(5-cyano-1H-indol-3-yl)...
Active IngredientVilazodone hydrochloride
Dosage FormTablet
RouteOral
Strength10mg; 40mg; 20mg
Market StatusPrescription
CompanyForest Labs

4.2 Therapeutic Uses

Antidepressant

National Library of Medicine, SIS; ChemIDplus Lite Record for Vilazodone (163521-12-8). Available from, as of May 30, 2014: https://chem.sis.nlm.nih.gov/chemidplus/chemidlite.jsp


Viibryd is indicated for the treatment of major depressive disorder (MDD). The efficacy of Viibryd was established in two 8-week, randomized, double-blind, placebo-controlled trials in adult patients with a diagnosis of MDD. Major depressive disorder consists of one or more major depressive episodes. A major depressive episode (DSM-IV-TR) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation. /Included in US product label/

NIH; DailyMed. Current Medication Information for Viibryd (Vilazodone Hydrochloride) Tablet Viibryd (Vilazodone Hydrochloride) Kit (Revised: July 2014). Available from, as of July 30, 2014: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4c55ccfb-c4cf-11df-851a-0800200c9a66


EXPL THER Sexual dysfunction is common in major depressive disorder (MDD), and many serotonergic antidepressants adversely affect sexual function. Vilazodone, a novel serotonin (5-HT) reuptake inhibitor and 5-HT1A partial agonist approved for MDD, exerts its effects at the 5-HT transporter and at both presynaptic and postsynaptic 5-HT1A receptors. This mechanism may limit sexual dysfunction. AIM: To summarize effects of vilazodone (40 mg/day, with food) on sexual function in adults with MDD, /data was used from/ three Phase III studies: two 8-week, placebo-controlled studies and a 52-week open-label study . Sexual function was assessed by analyzing changes from baseline to end of treatment (EOT) using validated measures. Population included 869 patients (vilazodone, 436; placebo, 433) from placebo-controlled studies and 599 patients from the open-label study. Sexual dysfunction prevalence was high (50%, men; 68%, women) before treatment and declined during treatment in vilazodone and placebo groups, indicating improvement on average. At EOT, stable/improved sexual function was observed in > or = 91% of patients in placebo-controlled studies; treatment group differences in sexual dysfunction at EOT were not statistically significant for either sex. Differences vs. placebo in changes from baseline of sexual function scores were small and were generally not statistically significant; effect sizes (Cohen's D) were generally of low magnitude. In the placebo-controlled studies, 8.0% of vilazodone-treated patients and 0.9% of placebo-treated patients reported > or = 1 sexual-function-related treatment-emergent adverse event (P<0.001). Half of men and two thirds of women with MDD had sexual dysfunction at baseline; sexual function improved on average in both vilazodone and placebo groups. Results suggest that vilazodone may have a small adverse impact on sexual function in adults with MDD relative to the high prevalence of sexual dysfunction at baseline.

PMID:23216998 Clayton AH et al; J Sex Med 10 (10): 2465-76 (2013)


4.3 Drug Warning

/BOXED WARNING/ WARNING: SUICIDAL THOUGHTS AND BEHAVIORS. Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older. In patients of all ages who are started on antidepressant therapy, monitor closely for clinical worsening and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber. Viibryd is not approved for use in pediatric patients.

NIH; DailyMed. Current Medication Information for Viibryd (Vilazodone Hydrochloride) Tablet Viibryd (Vilazodone Hydrochloride) Kit (Revised: July 2014). Available from, as of July 30, 2014: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4c55ccfb-c4cf-11df-851a-0800200c9a66


Worsening of depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior may occur in both adult and pediatric patients with major depressive disorder or other psychiatric disorders, whether or not they are taking antidepressants. This risk may persist until clinically important remission occurs. Suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicide. However, there has been a long-standing concern that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment. Pooled analyses of short-term, placebo-controlled studies of antidepressants (i.e., selective serotonin-reuptake inhibitors (SSRIs) and other antidepressants) have shown an increased risk of suicidality in children, adolescents, and young adults (18-24 years of age) with major depressive disorder and other psychiatric disorders. An increased suicidality risk was not demonstrated with antidepressants compared with placebo in adults older than 24 years of age, and a reduced risk was observed in adults 65 years of age or older. The US Food and Drug Administration (FDA) recommends that all patients being treated with antidepressants for any indication be appropriately monitored and closely observed for clinical worsening, suicidality, and unusual changes in behavior, particularly during initiation of therapy (i.e., the first few months) and during periods of dosage adjustments. Families and caregivers of patients being treated with antidepressants for major depressive disorder or other indications, both psychiatric and nonpsychiatric, also should be advised to monitor patients on a daily basis for the emergence of agitation, irritability, or unusual changes in behavior as well as the emergence of suicidality, and to report such symptoms immediately to a health-care provider. Although a causal relationship between the emergence of symptoms such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, and/or mania and either the worsening of depression and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality. Consequently, consideration should be given to changing the therapeutic regimen or discontinuing therapy in patients whose depression is persistently worse or in patients experiencing emergent suicidality or symptoms that might be precursors to worsening depression or suicidality, particularly if such manifestations are severe, abrupt in onset, or were not part of the patient's presenting symptoms. If a decision is made to discontinue therapy, vilazodone dosage should be tapered as rapidly as is feasible but consideration should be given to the risks of abrupt discontinuance. FDA also recommends that the drugs be prescribed in the smallest quantity consistent with good patient management, in order to reduce the risk of overdosage.

American Society of Health-System Pharmacists 2014; Drug Information 2014. Bethesda, MD. 2014, p. 2455


Potentially life-threatening serotonin syndrome or neuroleptic malignant syndrome (NMS)-like reactions have been reported with antidepressants alone, but particularly with concurrent use of other serotonergic drugs (including serotonin (5-hydroxytryptamine; 5-HT) type 1 receptor agonists (triptans)), drugs that impair the metabolism of serotonin (e.g., MAO inhibitors), or antipsychotics or other dopamine antagonists. Manifestations of serotonin syndrome may include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination), and/or GI symptoms (e.g., nausea, vomiting, diarrhea). In its most severe form, serotonin syndrome may resemble NMS, which is characterized by hyperthermia, muscle rigidity, autonomic instability with possible rapid fluctuation in vital signs, and mental status changes. Patients receiving vilazodone should be monitored for the development of serotonin syndrome or NMS-like signs and symptoms. Concurrent or recent (i.e., within 2 weeks) therapy with MAO inhibitors intended to treat depression is contraindicated. If concurrent therapy with vilazodone and a 5-HT1 receptor agonist (triptan) is clinically warranted, the patient should be observed carefully, particularly during initiation of therapy, when dosage is increased, or when another serotonergic agent is initiated. Concomitant use of vilazodone and serotonin precursors (e.g., tryptophan) is not recommended. If signs and symptoms of serotonin syndrome or NMS occur, treatment with vilazodone and any concurrently administered serotonergic or antidopaminergic agents, including antipsychotic agents, should be immediately discontinued and supportive and symptomatic treatment initiated.

American Society of Health-System Pharmacists 2014; Drug Information 2014. Bethesda, MD. 2014, p. 2455


Infants exposed to selective serotonin-reuptake inhibitors (SSRIs) in pregnancy may have an increased risk for persistent pulmonary hypertension of the newborn (PPHN). PPHN occurs in 1-2 per 1,000 live births in the general population and is associated with substantial neonatal morbidity and mortality. Several recent epidemiologic studies suggest a positive statistical association between SSRI use (including Viibryd) in pregnancy and PPHN. Other studies do not show a significant statistical association.

NIH; DailyMed. Current Medication Information for Viibryd (Vilazodone Hydrochloride) Tablet Viibryd (Vilazodone Hydrochloride) Kit (Revised: July 2014). Available from, as of July 30, 2014: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4c55ccfb-c4cf-11df-851a-0800200c9a66


For more Drug Warnings (Complete) data for Vilazodone (16 total), please visit the HSDB record page.


4.4 Drug Indication

Vilazodone is approved for treatment of major depressive disorder.


FDA Label


5 Pharmacology and Biochemistry
5.1 Pharmacology

Vilazodone increases serotonin levels in the brain by inhibiting the reuptake of serotonin while acting as a partial agonist on serotonin-1A receptors. Due to this activity vilazodone has sometimes been referred to as a selective partial agonist and reuptake inhibitor (SPARI).


5.2 MeSH Pharmacological Classification

Antidepressive Agents

Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. (See all compounds classified as Antidepressive Agents.)


Selective Serotonin Reuptake Inhibitors

Compounds that specifically inhibit the reuptake of serotonin in the brain. (See all compounds classified as Selective Serotonin Reuptake Inhibitors.)


Serotonin 5-HT1 Receptor Agonists

Endogenous compounds and drugs that specifically stimulate SEROTONIN 5-HT1 RECEPTORS. Included under this heading are agonists for one or more of the specific 5-HT1 receptor subtypes. (See all compounds classified as Serotonin 5-HT1 Receptor Agonists.)


5.3 ATC Code

N - Nervous system

N06 - Psychoanaleptics

N06A - Antidepressants

N06AX - Other antidepressants

N06AX24 - Vilazodone


5.4 Absorption, Distribution and Excretion

Absorption

Vilazodone's bioavailability is 72% when taken with food.


Route of Elimination

1% of the dose is recovered unchanged in the urine and 2% of the dose is recovered unchanged in the feces.


Volume of Distribution

Vilazodone's volume of distribution is unknown but large


Clearance

Clearance of vilazodone is 19.9-25.1L/h in patients with mild to moderate renal impairment compared to 26.4-26.9L/h in healthy controls.


Vilazodone concentrations peak at a median of 4-5 hours (Tmax) after administration and decline with a terminal half-life of approximately 25 hours. The absolute bioavailability of vilazodone is 72% with food. Administration of VIIBRYD with food (high fat or light meal) increases oral bioavailability (Cmax increased by approximately 147-160%, and AUC increased by approximately 64-85%).

NIH; DailyMed. Current Medication Information for Viibryd (Vilazodone Hydrochloride) Tablet Viibryd (Vilazodone Hydrochloride) Kit (Revised: July 2014). Available from, as of July 30, 2014: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4c55ccfb-c4cf-11df-851a-0800200c9a66


Vilazodone is widely distributed and approximately 96-99% protein-bound.

NIH; DailyMed. Current Medication Information for Viibryd (Vilazodone Hydrochloride) Tablet Viibryd (Vilazodone Hydrochloride) Kit (Revised: July 2014). Available from, as of July 30, 2014: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4c55ccfb-c4cf-11df-851a-0800200c9a66


Vilazodone is excreted into the milk of lactating rats.

NIH; DailyMed. Current Medication Information for Viibryd (Vilazodone Hydrochloride) Tablet Viibryd (Vilazodone Hydrochloride) Kit (Revised: July 2014). Available from, as of July 30, 2014: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4c55ccfb-c4cf-11df-851a-0800200c9a66


5.5 Metabolism/Metabolites

Vilazodone is mainly metabolized by cytochrome P450(CYP)3A4 and also to a minor extent by CYP2C19 and CYP 2D6. Although the metabolic pathway for vilazodone has not been fully studied, a proposed mechanism for metabolism in rats was published in 2017.


Viibryd is extensively metabolized through CYP and non-CYP pathways (possibly by carboxylesterase), with only 1% of the dose recovered in the urine and 2% of the dose recovered in the feces as unchanged vilazodone. CYP3A4 is primarily responsible for its metabolism among CYP pathways, with minor contributions from CYP2C19 and CYP2D6. In vitro studies with human microsomes and human hepatocytes indicate that vilazodone is unlikely to inhibit or induce the metabolism of other CYP (except for CYP2C8) substrates; and an in vivo study with probe substrates for CYP2C19, 2D6 and 3A4 showed vilazodone did not alter the pharmacokinetics of the probe substrates. However, an in vivo study with probe substrate for CYP2C19 demonstrated a minor induction of CYP2C19. Strong inhibitors of CYP3A4 (e.g., ketoconazole) can reduce the metabolism of vilazodone in vivo and increase exposure. Conversely, strong inducers of CYP3A4 (e.g., carbamazepine) can decrease vilazodone exposure.

NIH; DailyMed. Current Medication Information for Viibryd (Vilazodone Hydrochloride) Tablet Viibryd (Vilazodone Hydrochloride) Kit (Revised: July 2014). Available from, as of July 30, 2014: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4c55ccfb-c4cf-11df-851a-0800200c9a66


5.6 Biological Half-Life

25 hours. Other studies show a half life of 245.2h with a single 40mg dose and 28.93.2h with repeated doses.


Vilazodone /has/ a terminal half-life of approximately 25 hours.

NIH; DailyMed. Current Medication Information for Viibryd (Vilazodone Hydrochloride) Tablet Viibryd (Vilazodone Hydrochloride) Kit (Revised: July 2014). Available from, as of July 30, 2014: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4c55ccfb-c4cf-11df-851a-0800200c9a66


5.7 Mechanism of Action

Vilazodone selectively inhibits serotonin reuptake in the central nervous system as well as acting as a partial agonist of 5HT-1A receptors. The exact mechanism for how these effects translate to its antidepressant effects are not known, though there is an association between these effects and antidepressive activity.


Vilazodone has been reported to be an inhibitor of 5-hydoxytryptamine (5-HT) reuptake and a partial agonist at 5-HT1A receptors. Using [35S]GTPgammaS binding in rat hippocampal tissue, vilazodone was demonstrated to have an intrinsic activity comparable to the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). Vilazodone (1-10 mg/kg p.o.) dose-dependently displaced in vivo [3H]DASB (N,N-dimethyl-2-(2-amino-4-cyanophenylthio)benzylamine) binding from rat cortex and hippocampus, indicating that vilazodone occupies 5-HT transporters in vivo. Using in vivo microdialysis, vilazodone (10 mg/kg p.o.) was demonstrated to cause a 2-fold increase in extracellular 5-HT but no change in noradrenaline or dopamine levels in frontal cortex of freely moving rats. In contrast, administration of 8-OH-DPAT (0.3 mg/kg s.c.), either alone or in combination with a serotonin specific reuptake inhibitor (SSRI; paroxetine, 3 mg/kg p.o.), produced no increase in cortical 5-HT whilst increasing noradrenaline and dopamine 2 and 4 fold, respectively. A 2-fold increase in extracellular 5-HT levels (but no change in noradrenaline or dopamine levels) was observed after combination of the 5-HT(1A) receptor antagonist, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(pyridinyl)cyclohexanecarboxamide) (WAY-100635; 0.3 mg/kg s.c.) and paroxetine (3 mg/kg p.o.). In summary, vilazodone behaved as a high efficacy partial agonist at the rat hippocampal 5-HT1A receptors in vitro and occupied 5-HT transporters in vivo. In vivo vilazodone induced a selective increase in extracellular levels of 5-HT in the rat frontal cortex. This profile was similar to that seen with a 5-HT1A receptor antagonist plus an SSRI but in contrast to 8-OH-DPAT either alone or in combination with paroxetine.

PMID:15740724 Hughes ZA et al; Eur J Pharmacol 510 (1-2): 49-57 (2005)


The mechanism of the antidepressant effect of vilazodone is not fully understood but is thought to be related to its enhancement of serotonergic activity in the CNS through selective inhibition of serotonin reuptake. Vilazodone is also a partial agonist at serotonergic 5-HT1A receptors; however, the net result of this action on serotonergic transmission and its role in vilazodone's antidepressant effect are unknown.

NIH; DailyMed. Current Medication Information for Viibryd (Vilazodone Hydrochloride) Tablet Viibryd (Vilazodone Hydrochloride) Kit (Revised: July 2014). Available from, as of July 30, 2014: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4c55ccfb-c4cf-11df-851a-0800200c9a66


The recently approved antidepressant vilazodone, a serotonin (5-HT)1A receptor partial agonist/selective 5-HT reuptake inhibitor offers new possibilities to study the underlying mechanisms of depression pharmacotherapy and of 5-HT augmenting antidepressants. ... 5-HT levels /were measured/ in two subregions of the rat prefrontal cortex by microdialysis, and 5-hydroxytryptophan (5-HTP) accumulation and tissue 5-HT concentrations ex vivo. Vilazodone-induced maximal 5-HT levels were similar in the medial and the lateral cortex and were up to sixfold higher than those induced by paroxetine, citalopram, or fluoxetine tested in parallel. Depolarization/autoreceptor-insensitive 5-HT release by vilazodone could be excluded. The citalopram (1 uM, locally infused)-induced increase of 5-HT was further increased by vilazodone (1 mg/kg i.p.), but not by citalopram (10 mg/kg i.p.). Unlike fluoxetine, vilazodone-induced extracellular 5-HT output was not potentiated by cotreatment with the 5-HT1A receptor blocker N-[2-(4-{2-methoxyphenyl}-1-piperazinyl)-ethyl]-N-2-pyridinylcyclohexanecarboxamide (WAY 100635). In contrast to fluoxetine, vilazodone exhibited intrinsic 5-HT1A agonist activity: it reduced, similar to (+/-)-8-hydroxy-2-(dipropylamino)-tetralin (8-OH-DPAT), 5-HTP accumulation in striatum and n. raphe of reserpinized rats. Hence, vilazodone's agonistic actions must be 5-HT1A receptor-related since endogenous 5-HT is lacking in the reserpine-depleted animal. In spite of high intrinsic 5-HT1A activity in reserpinized rats, the net effect of vilazodone at release-regulating 5-HT1A autoreceptors must be inhibitory, leading to markedly increased 5-HT output. Another possibility is that vilazodone rapidly desensitizes autoinhibitory 5-HT1A receptors by an unknown mechanism.

PMID:24419272 van Amsterdam C, Seyfried CA; Psychopharmacology 231 (12): 2547-58 (2014)


This study examined the effect of vilazodone, a combined serotonin (5-HT) reuptake inhibitor and 5-HT(1A) receptor partial agonist, paroxetine and fluoxetine on the sensitivity of 5-HT(1A) autoreceptors of serotonergic dorsal raphe nucleus neurons in rats. These effects were assessed by determining the intravenous dose of (+/-)-8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT) required to suppress the basal firing rate of these neurons by 50% (ID50) in anesthetized rats using in vivo electrophysiology. 5-HT uptake inhibition was determined by the ability of the compounds to reverse (+/-)-p-chloroamphetamine (PCA)-induced rat hypothalamic 5-HT depletion ex vivo. Acute vilazodone administration (0.63 and 2.1 umol/kg, s.c.), compared with vehicle, significantly increased (2-3-fold) the ID50 of 8-OH-DPAT at 4 hr, but not 24 hr after administration. Subchronic administration (3 days) significantly increased the ID50 value at 4 hr (3-4-fold) and at 24 hr (approximately 2-fold). In contrast, paroxetine and fluoxetine at doses that were supramaximal for 5-HT uptake inhibition did not significantly alter the ID50 value of 8-OH-DPAT after acute or subchronic administration. Vilazodone antagonized the action of PCA 3.5 hr and 5 hr after a single dose (ID50 1.49 and 0.46 umol/kg, s.c., respectively), but was inactive 18 hr post-administration, corroborating the electrophysiological results at 24 hr following acute administration. The results are consistent with the concept of rapid and, following repeated treatment, prolonged inhibition of 5-HT(1A) autoreceptors by vilazodone. This effect could occur by either direct interaction with, or desensitization of, these receptors, an effect which cannot be ascribed to vilazodone's 5-HT reuptake inhibiting properties.

PMID:23872377 Ashby CR Jr et al; Eur J Pharmacol 714 (1-3): 359-65 (2013)


API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"VILAZODONE HYDROCHLORIDE","year":"2021","qtr":"Q1","strtotime":1616092200,"product":"VILAZODONE HYDROCHLORIDE (GROUP:B) (TAX INVOICE NO:2900205909 DATE:16.03.2021","address":"H.NO. 115\/2RT, SECOND FLOOR,SANJEEVA REDDY NAGAR","city":"HYDERABAD","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"SHENZHEN","customer":"DONGGUAN YANGZHIKANG MEDICINE ","customerCountry":"CHINA","quantity":"5.10","actualQuantity":"5.1","unit":"KGS","unitRateFc":"4787.8","totalValueFC":"24165.7","currency":"USD","unitRateINR":344960.58823529416,"date":"19-Mar-2021","totalValueINR":"1759299","totalValueInUsd":"24165.7","indian_port":"HYDERABAD AIR","hs_no":"29349990","bill_no":"9489478","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"H.NO. 115\/2RT, SECOND FLOOR,SANJEEVA REDDY NAGAR, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q2","strtotime":1622658600,"product":"VILAZODONE HYDROCHLORIDE (GROUP:B) (TAX INVOICE NO:2900215111 DATE:28.05.2021","address":"H.NO. 115\/2RT, SECOND FLOOR,SANJEEVA REDDY NAGAR","city":"HYDERABAD","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"SHENZHEN","customer":"SUNSHINE LAKE PHARMA","customerCountry":"CHINA","quantity":"16.00","actualQuantity":"16","unit":"KGS","unitRateFc":"4844.9","totalValueFC":"75942.7","currency":"USD","unitRateINR":349078.1875,"date":"03-Jun-2021","totalValueINR":"5585251","totalValueInUsd":"75942.7","indian_port":"HYDERABAD AIR","hs_no":"29349990","bill_no":"2196815","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"H.NO. 115\/2RT, SECOND FLOOR,SANJEEVA REDDY NAGAR, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1628533800,"product":"VILAZODONE HYDROCHLORIDE (TAX INVOICE NO","address":"H.NO. 115\/2RT, SECOND FLOOR,SANJEEVA REDDY NAGAR","city":"HYDERABAD","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"BASLE","customer":"AIRPHARM","customerCountry":"SWITZERLAND","quantity":"22.90","actualQuantity":"22.9","unit":"KGS","unitRateFc":"5445","totalValueFC":"122870.6","currency":"USD","unitRateINR":397947.59825327515,"date":"10-Aug-2021","totalValueINR":"9113000","totalValueInUsd":"122870.6","indian_port":"HYDERABAD AIR","hs_no":"29349990","bill_no":"3756758","productDescription":"API","marketType":"REGULATED MARKET","country":"SWITZERLAND","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"H.NO. 115\/2RT, SECOND FLOOR,SANJEEVA REDDY NAGAR, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1631039400,"product":"PHARMACEUTICAL RAW MATERIAL VILAZODONE H","address":"407\/408,SHARDA CHAMBERS,NEW MARINE LINES,","city":"MUMBAI, MAHARASHTRA.","supplier":"BDR PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"CAIRO","customer":"TEORAFPH","customerCountry":"EGYPT","quantity":"30.00","actualQuantity":"30","unit":"KGS","unitRateFc":"3600","totalValueFC":"105714.7","currency":"USD","unitRateINR":259200,"date":"08-Sep-2021","totalValueINR":"7776000","totalValueInUsd":"105714.7","indian_port":"BOMBAY AIR","hs_no":"29349990","bill_no":"4448425","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"EGYPT","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"407\/408,SHARDA CHAMBERS,NEW MARINE LINES,, MUMBAI, MAHARASHTRA.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1631557800,"product":"VILAZODONE HYDROCHLORIDE (TAX INVOICE NO","address":"H.NO. 115\/2RT, SECOND FLOOR,SANJEEVA REDDY NAGAR","city":"HYDERABAD","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"SHANGHAI","customer":"SUNSHINE LAKE PHARMA","customerCountry":"CHINA","quantity":"9.00","actualQuantity":"9","unit":"KGS","unitRateFc":"4850","totalValueFC":"42538.8","currency":"USD","unitRateINR":347666.66666666669,"date":"14-Sep-2021","totalValueINR":"3129000","totalValueInUsd":"42538.8","indian_port":"HYDERABAD AIR","hs_no":"29349990","bill_no":"4573483","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"H.NO. 115\/2RT, SECOND FLOOR,SANJEEVA REDDY NAGAR, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1631644200,"product":"PHARMACEUTICAL RAW MATERIAL VILAZODONE H","address":"407\/408,SHARDA CHAMBERS,NEW MARINE LINES,","city":"MUMBAI, MAHARASHTRA.","supplier":"BDR PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"CAIRO","customer":"TEORAFPH","customerCountry":"EGYPT","quantity":"30.00","actualQuantity":"30","unit":"KGS","unitRateFc":"3600","totalValueFC":"105714.7","currency":"USD","unitRateINR":259200,"date":"15-Sep-2021","totalValueINR":"7776000","totalValueInUsd":"105714.7","indian_port":"BOMBAY AIR","hs_no":"29349990","bill_no":"4587036","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"EGYPT","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"407\/408,SHARDA CHAMBERS,NEW MARINE LINES,, MUMBAI, MAHARASHTRA.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1632162600,"product":"VILAZODONE HYDROCHLORIDE (ALONG WITH FRE","address":"8-3-166\/6&7, IIND FLOOR,SREE ARCADEERRAGADDA","city":"HYDERABAD-AP","supplier":"SYMED LABS","supplierCountry":"INDIA","foreign_port":"CAIRO","customer":"AVERROES PHARMA FOR ","customerCountry":"EGYPT","quantity":"20.00","actualQuantity":"20","unit":"KGS","unitRateFc":"2400","totalValueFC":"47269.8","currency":"USD","unitRateINR":173850,"date":"21-Sep-2021","totalValueINR":"3477000","totalValueInUsd":"47269.8","indian_port":"HYDERABAD AIR","hs_no":"29349990","bill_no":"4749803","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"EGYPT","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"8-3-166\/6&7, IIND FLOOR,SREE ARCADEERRAGADDA, HYDERABAD-AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1645986600,"product":"VILAZODONE HCL","address":"H.NO. 8-2-337, BESIDE TV9 OFFICE, ROAD NO.3, BANJARA HILLS, Contact N","city":"HYDERABAD","supplier":"DR. REDDY\\'S LABORATORIES","supplierCountry":"INDIA","foreign_port":"PHILADELPHIA METROP","customer":"INVAGEN PHARMACEUTICALS INC","customerCountry":"UNITED STATES","quantity":"40.00","actualQuantity":"40","unit":"KGS","unitRateFc":"5850","totalValueFC":"224555.7","currency":"USD","unitRateINR":420800,"date":"28-Feb-2022","totalValueINR":"16832000","totalValueInUsd":"224555.7","indian_port":"HYDERABAD AIR","hs_no":"29141990","bill_no":"8568501","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"H.NO. 8-2-337, BESIDE TV9 OFFICE, ROAD NO.3, BANJARA HILLS, Contact N, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1646332200,"product":"VILAZODONE HYDROCHLORIDE (OTHER) (LUT (","address":"407\/408 SHARDA CHAMBERS,NEW MARINE LINES","city":"MUMBAI,MAHARASHTRA","supplier":"BDR PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"CAIRO","customer":"TEORAFPH","customerCountry":"EGYPT","quantity":"20.00","actualQuantity":"20","unit":"KGS","unitRateFc":"3000","totalValueFC":"58725.1","currency":"USD","unitRateINR":223800,"date":"04-Mar-2022","totalValueINR":"4476000","totalValueInUsd":"58725.1","indian_port":"BOMBAY AIR","hs_no":"29349990","bill_no":"8697337","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"EGYPT","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"407\/408 SHARDA CHAMBERS,NEW MARINE LINES, MUMBAI,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1652985000,"product":"VILAZODONE HYDROCHLORIDE (TAX INVOICE NO","address":"MSN HOUSE ,PLOT NO. C-24, INDUSTRIAL ESTATE,SANATHNAGAR,HYDER","city":"HYDERABAD","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"RENATA LIMITED","customerCountry":"BANGLADESH","quantity":"30.00","actualQuantity":"30","unit":"KGS","unitRateFc":"4000","totalValueFC":"119258.8","currency":"USD","unitRateINR":307233.33333333331,"date":"20-May-2022","totalValueINR":"9217000","totalValueInUsd":"119258.8","indian_port":"HYDERABAD AIR","hs_no":"29349990","bill_no":"1520088","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE ,PLOT NO. C-24, INDUSTRIAL ESTATE,SANATHNAGAR,HYDER, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1656441000,"product":"VILAZODONE HYDROCHLORIDE","address":"MSN HOUSE ,PLOT NO. C-24, INDUSTRIAL ESTATE,SANATHNAGAR,HYDER","city":"HYDERABAD","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"TO THE ORDER OF.,","customerCountry":"BANGLADESH","quantity":"20.00","actualQuantity":"20","unit":"KGS","unitRateFc":"4000","totalValueFC":"79138.3","currency":"USD","unitRateINR":308700,"date":"29-Jun-2022","totalValueINR":"6174000","totalValueInUsd":"79138.3","indian_port":"HYDERABAD AIR","hs_no":"29349990","bill_no":"2466303","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE ,PLOT NO. C-24, INDUSTRIAL ESTATE,SANATHNAGAR,HYDER, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1656613800,"product":"VILAZODONE HYDROCHLORIDE","address":"MSN HOUSE ,PLOT NO. C-24, INDUSTRIAL ESTATE,SANATHNAGAR,HYDER","city":"HYDERABAD","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"TO THE ORDER OF.,","customerCountry":"BANGLADESH","quantity":"20.00","actualQuantity":"20","unit":"KGS","unitRateFc":"4000","totalValueFC":"77644.2","currency":"USD","unitRateINR":308700,"date":"01-Jul-2022","totalValueINR":"6174000","totalValueInUsd":"77644.2","indian_port":"HYDERABAD AIR","hs_no":"29349990","bill_no":"2528417","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE ,PLOT NO. C-24, INDUSTRIAL ESTATE,SANATHNAGAR,HYDER, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1658687400,"product":"VILAZODONE HCL","address":"H.NO. 8-2-337, BESIDE TV9 OFFICE, ROAD NO.3, BANJARA HILLS, Contact N","city":"HYDERABAD","supplier":"DR. REDDY\\'S LABORATORIES","supplierCountry":"INDIA","foreign_port":"PHILADELPHIA METROP","customer":"COMPANY","customerCountry":"UNITED STATES","quantity":"32.48","actualQuantity":"32.48","unit":"KGS","unitRateFc":"5850","totalValueFC":"179824.2","currency":"USD","unitRateINR":440240.14778325125,"date":"25-Jul-2022","totalValueINR":"14299000","totalValueInUsd":"179824.2","indian_port":"HYDERABAD AIR","hs_no":"29141990","bill_no":"3060331","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"H.NO. 8-2-337, BESIDE TV9 OFFICE, ROAD NO.3, BANJARA HILLS, Contact N, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1659551400,"product":"VILAZODONE HCL","address":"H.NO. 8-2-337, BESIDE TV9 OFFICE, ROAD NO.3, BANJARA HILLS, Contact N","city":"HYDERABAD","supplier":"DR. REDDY\\'S LABORATORIES","supplierCountry":"INDIA","foreign_port":"NEW YORK - JOHN F. K","customer":"COMPANY","customerCountry":"UNITED STATES","quantity":"63.02","actualQuantity":"63.02","unit":"KGS","unitRateFc":"5850","totalValueFC":"366269.2","currency":"USD","unitRateINR":462440.49508092669,"date":"04-Aug-2022","totalValueINR":"29143000","totalValueInUsd":"366269.2","indian_port":"HYDERABAD AIR","hs_no":"29141990","bill_no":"3304937","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"H.NO. 8-2-337, BESIDE TV9 OFFICE, ROAD NO.3, BANJARA HILLS, Contact N, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1663785000,"product":"VILAZODONE HCL","address":"H.NO. 8-2-337, BESIDE TV9 OFFICE, ROAD NO.3, BANJARA HILLS, Contact N","city":"HYDERABAD","supplier":"DR. REDDY\\'S LABORATORIES","supplierCountry":"INDIA","foreign_port":"NEW YORK - JOHN F. K","customer":"COMPANY","customerCountry":"UNITED STATES","quantity":"8.40","actualQuantity":"8.4","unit":"KGS","unitRateFc":"5850","totalValueFC":"46206","currency":"USD","unitRateINR":440833.33333333331,"date":"22-Sep-2022","totalValueINR":"3703000","totalValueInUsd":"46206","indian_port":"HYDERABAD AIR","hs_no":"29141990","bill_no":"4363471","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"H.NO. 8-2-337, BESIDE TV9 OFFICE, ROAD NO.3, BANJARA HILLS, Contact N, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1667413800,"product":"VILAZODONE HYDROCHLORIDE","address":"ALEMBIC ROAD VADODARA Contact No: 919727727339","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LIMITED","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"TO THE ORDER OF","customerCountry":"ARGENTINA","quantity":"20.00","actualQuantity":"20","unit":"KGS","unitRateFc":"7200","totalValueFC":"135787.7","currency":"USD","unitRateINR":554100,"date":"03-Nov-2022","totalValueINR":"11082000","totalValueInUsd":"135787.7","indian_port":"AHMEDABAD AIR","hs_no":"29349990","bill_no":"5228071","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"ALEMBIC ROAD VADODARA Contact No: 919727727339, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1680633000,"product":"VILAZODONE HYDROCHLORIDE","address":"ALEMBIC ROAD VADODARA Contact No: 919727727339","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LIMITED","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"TO THE ORDER OF","customerCountry":"ARGENTINA","quantity":"20.00","actualQuantity":"20","unit":"KGS","unitRateFc":"7200","totalValueFC":"134758.9","currency":"USD","unitRateINR":552200,"date":"05-Apr-2023","totalValueINR":"11044000","totalValueInUsd":"134758.9","indian_port":"AHMEDABAD AIR","hs_no":"29349990","bill_no":"9093121","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"ALEMBIC ROAD VADODARA Contact No: 919727727339, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1688581800,"product":"VILAZODONE HYDROCHLORIDE","address":"ALEMBIC ROAD VADODARA Contact No: 919727727339","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LIMITED","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"TO THE ORDER OF","customerCountry":"ARGENTINA","quantity":"20.00","actualQuantity":"20","unit":"KGS","unitRateFc":"7200","totalValueFC":"133313.8","currency":"USD","unitRateINR":547849.98450000002,"date":"06-Jul-2023","totalValueINR":"10956999.69","totalValueInUsd":"133313.8","indian_port":"AHMEDABAD AIR","hs_no":"29349990","bill_no":"0","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"ALEMBIC ROAD VADODARA Contact No: 919727727339, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1694802600,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS (API)EXPORT INVOICE NUMBER: F32418002175 DT.31.08.2023 VILAZODONE HYDROCHLORIDE","address":"PLOT 170-172, CHANDRAMOULI,INDUSTR","city":"SOLAPUR,MAHARASHTRA","supplier":"GLENMARK PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"TO THE ORDER.,","customerCountry":"ARGENTINA","quantity":"17.70","actualQuantity":"17.7","unit":"KGS","unitRateFc":"6310","totalValueFC":"109700","currency":"USD","unitRateINR":514463.27683615818,"date":"16-Sep-2023","totalValueINR":"9106000","totalValueInUsd":"109700","indian_port":"Bombay Air","hs_no":"29420090","bill_no":"3985062","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"PLOT 170-172, CHANDRAMOULI,INDUSTR, SOLAPUR,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1706985000,"product":"VILAZODONE HYDROCHLORIDE","address":"PLOT NO. C-24, INDUSTRIAL ESTATE,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"BASLE","customer":"AIRPHARM","customerCountry":"SWITZERLAND","quantity":"17.90","actualQuantity":"17.9","unit":"KGS","unitRateFc":"5940","totalValueFC":"105232.8","currency":"USD","unitRateINR":487796.71508379886,"date":"04-Feb-2024","totalValueINR":"8731561.2","totalValueInUsd":"105232.8","indian_port":"Hyderabad Air","hs_no":"29349990","bill_no":"7256812","productDescription":"API","marketType":"REGULATED MARKET","country":"SWITZERLAND","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"PLOT NO. C-24, INDUSTRIAL ESTATE,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1706985000,"product":"VILAZODONE HYDROCHLORIDE","address":"PLOT NO. C-24, INDUSTRIAL ESTATE,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"BASLE","customer":"AIRPHARM","customerCountry":"SWITZERLAND","quantity":"104.80","actualQuantity":"104.8","unit":"KGS","unitRateFc":"5940","totalValueFC":"616159.9","currency":"USD","unitRateINR":487835.0992366412,"date":"04-Feb-2024","totalValueINR":"51125118.4","totalValueInUsd":"616159.9","indian_port":"Hyderabad Air","hs_no":"29349990","bill_no":"7256812","productDescription":"API","marketType":"REGULATED MARKET","country":"SWITZERLAND","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"PLOT NO. C-24, INDUSTRIAL ESTATE,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1712773800,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS (API)EXPORT INVOICE NUMBER : F32418005381 DT. 31.03.2024 VILAZODONE HYDROCHLORIDE","address":"PLOT 170-172, CHANDRAMOULI,INDUSTR","city":"SOLAPUR,MAHARASHTRA","supplier":"GLENMARK PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES","customer":"TO THE ORDER","customerCountry":"ARGENTINA","quantity":"10.53","actualQuantity":"10.53","unit":"KGS","unitRateFc":"6310","totalValueFC":"65717.4","currency":"USD","unitRateINR":521166.7787274454,"date":"11-Apr-2024","totalValueINR":"5487886.18","totalValueInUsd":"65717.4","indian_port":"Bombay Air","hs_no":"29420090","bill_no":"9056834","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"PLOT 170-172, CHANDRAMOULI,INDUSTR, SOLAPUR,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1716143400,"product":"VILAZODONE HYDROCHLORIDE","address":"PLOT NO. C-24, INDUSTRIAL ESTATE,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"ULKAR HOLDING","customerCountry":"TURKEY","quantity":"2.00","actualQuantity":"2","unit":"KGS","unitRateFc":"7300","totalValueFC":"14391.3","currency":"USD","unitRateINR":599787.5,"date":"20-May-2024","totalValueINR":"1199575","totalValueInUsd":"14391.3","indian_port":"Hyderabad Air","hs_no":"29349990","bill_no":"1014981","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"PLOT NO. C-24, INDUSTRIAL ESTATE,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1716834600,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS (API)(PHARMACEUTICALS RAW MATERIAL FOR PHARMA INDUSTRIES) - VILAZODONE HYDROCHLORIDE","address":"ALEMBIC ROAD","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LIMITED","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"TO THE ORDER OF","customerCountry":"ARGENTINA","quantity":"20.00","actualQuantity":"20","unit":"KGS","unitRateFc":"6900","totalValueFC":"129329.5","currency":"USD","unitRateINR":539007.82300000009,"date":"28-May-2024","totalValueINR":"10780156.46","totalValueInUsd":"129329.5","indian_port":"Ahmedabad Air","hs_no":"29349990","bill_no":"1232998","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"ALEMBIC ROAD, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1717007400,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS (API)EXPORT INVOICE NUMBER : F32518000704 DT. 27.05.2024 VILAZODONE HYDROCHLORIDE","address":"PLOT 170-172, CHANDRAMOULI,INDUSTR","city":"SOLAPUR,MAHARASHTRA","supplier":"GLENMARK PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES","customer":"TO THE ORDER","customerCountry":"ARGENTINA","quantity":"9.47","actualQuantity":"9.47","unit":"KGS","unitRateFc":"6310","totalValueFC":"58366.4","currency":"USD","unitRateINR":513736.51636747614,"date":"30-May-2024","totalValueINR":"4865084.81","totalValueInUsd":"58366.4","indian_port":"Bombay Air","hs_no":"29420090","bill_no":"1283007","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"PLOT 170-172, CHANDRAMOULI,INDUSTR, SOLAPUR,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1719599400,"product":"VILAZODONE HCL (OTHER)(LUT(ARN)NO:AD270324101144O DT: 15\/03\/2024)(TAX INV# MH2411600142 DT: 26\/06\/2024)","address":"407\/408,SHARDA CHAMBERS,","city":"MUMBAI, MAHARASHTRA.","supplier":"BDR PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"CAIRO","customer":"TERAMPHAIND","customerCountry":"EGYPT","quantity":"10.00","actualQuantity":"10","unit":"KGS","unitRateFc":"3000","totalValueFC":"29481.2","currency":"USD","unitRateINR":246107.02999999997,"date":"29-Jun-2024","totalValueINR":"2461070.3","totalValueInUsd":"29481.2","indian_port":"Bombay Air","hs_no":"29349990","bill_no":"2069102","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"EGYPT","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"407\/408,SHARDA CHAMBERS,, MUMBAI, MAHARASHTRA.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1724351400,"product":"VILAZODONE HYDROCHLORIDE","address":"PLOT NO. C-24, INDUSTRIAL ESTATE,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"ULKAR HOLDING","customerCountry":"TURKEY","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"7300","totalValueFC":"3543.3","currency":"USD","unitRateINR":594406,"date":"23-Aug-2024","totalValueINR":"297203","totalValueInUsd":"3543.3","indian_port":"Hyderabad Air","hs_no":"29349990","bill_no":"3418247","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"PLOT NO. C-24, INDUSTRIAL ESTATE,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1727375400,"product":"VILAZODONE HYDROCHLORIDE","address":"PLOT NO. C-24, INDUSTRIAL ESTATE,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"SAO PAULO - CONGONHA","customer":"LIBBS FARMACEUTICA","customerCountry":"BRAZIL","quantity":"117.40","actualQuantity":"117.4","unit":"KGS","unitRateFc":"6000","totalValueFC":"696824.7","currency":"USD","unitRateINR":497400,"date":"27-Sep-2024","totalValueINR":"58394760","totalValueInUsd":"696824.7","indian_port":"Hyderabad Air","hs_no":"29349990","bill_no":"4374293","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BRAZIL","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"PLOT NO. C-24, INDUSTRIAL ESTATE,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1630607400,"product":"VILAZODONE HYDROCHLORIDE (IMPORT FOR EXPORT)","address":"407\/408,SHARDA CHAMBERS,NEW MARINE LINES,","city":"MUMBAI, MAHARASHTRA.","supplier":"SHANGHAI KAIXIN PHARMACEUTICALS ","supplierCountry":"CHINA","foreign_port":"#N\/A","customer":"BDR PHARMACEUTICALS","customerCountry":"INDIA","quantity":"6.00","actualQuantity":"6","unit":"KGS","unitRateFc":"2225","totalValueFC":"13421.4","currency":"USD","unitRateINR":"164538.8","date":"03-Sep-2021","totalValueINR":"987232.5","totalValueInUsd":"13421.4","indian_port":"BOMBAY AIR","hs_no":"29349990","bill_no":"5297271","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"#N\/A","supplierAddress":"","customerAddress":"407\/408,SHARDA CHAMBERS,NEW MARINE LINES,"}]
19-Mar-2021
27-Sep-2024
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

read-more
read-more

Coating Systems & Additives

read-more
read-more

Direct Compression

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Controlled & Modified Release

read-more
read-more

Lubricants & Glidants

read-more
read-more

Co-Processed Excipients

read-more
read-more

Granulation

read-more
read-more

Topical

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Solubilizers

read-more
read-more

Parenteral

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Taste Masking

read-more
read-more

Emulsifying Agents

read-more
read-more

API Stability Enhancers

read-more
read-more

Coloring Agents

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Rheology Modifiers

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty